M Demirpence1, H Y Yasar1, A Colak2, B Akinci3, S Yener3, B Toprak2, I Karademirci2. 1. Tepecik Research and Training Hospital, Dept. of Endocrinology, Izmir, Turkey. 2. Tepecik Research and Training Hospital, Dept. of Biochemistry, Izmir, Turkey. 3. Dokuz Eylul University Hospital, Dept. of Endocrinology, Aydin, Turkey.
Abstract
OBJECTIVE: Mean platelet volume (MPV) and platelet function analysis have been studied before in acromegaly, but the effect of treatment on both parameters has not been evaluated. We aimed to investigate MPV and platelet function analysis in acromegalic patients after six-months of treatment. METHODS: Forty patients with active acromegaly and 36 healthy subjects were included in the study. Plasma glucose and lipids, fibrinogen, GH, IGF-1 levels, MPV and platelet function analysis were measured. All patients with acromegaly were re-evaluated six months after treatment. RESULTS: Fasting blood glucose (FBG), GH, IGF-1, fibrinogen levels and MPV values were significantly higher in acromegalic group compared with the control. Platelet function was enhanced significantly (pcol-ADP: 0.002, pcolepinephrine: 0.002). After 6 months of treatment FBG, serum GH, IGF-1, fibrinogen and MPV decreased and collagen/ADP- and collagen/epinephrine-closure times (CT) were increased. Acromegalic patients that were in remission with long-acting SSA after surgery had significantly higher fibrinogen levels and MPV and decreased collagen/epinephrine-CT with respect to the controls (pfibrinogen: 0.001, pMPV: 0.026, pcol-epinephrine: 0.037). CONCLUSION: Acromegaly was associated with increased MPV and enhanced platelet activity. Although growth hormone hypersecretion was controlled by surgery and medical treatment, these parameters did not improve - indicating a still increased risk for cardiovascular events.
OBJECTIVE: Mean platelet volume (MPV) and platelet function analysis have been studied before in acromegaly, but the effect of treatment on both parameters has not been evaluated. We aimed to investigate MPV and platelet function analysis in acromegalic patients after six-months of treatment. METHODS: Forty patients with active acromegaly and 36 healthy subjects were included in the study. Plasma glucose and lipids, fibrinogen, GH, IGF-1 levels, MPV and platelet function analysis were measured. All patients with acromegaly were re-evaluated six months after treatment. RESULTS: Fasting blood glucose (FBG), GH, IGF-1, fibrinogen levels and MPV values were significantly higher in acromegalic group compared with the control. Platelet function was enhanced significantly (pcol-ADP: 0.002, pcolepinephrine: 0.002). After 6 months of treatment FBG, serum GH, IGF-1, fibrinogen and MPV decreased and collagen/ADP- and collagen/epinephrine-closure times (CT) were increased. Acromegalic patients that were in remission with long-acting SSA after surgery had significantly higher fibrinogen levels and MPV and decreased collagen/epinephrine-CT with respect to the controls (pfibrinogen: 0.001, pMPV: 0.026, pcol-epinephrine: 0.037). CONCLUSION: Acromegaly was associated with increased MPV and enhanced platelet activity. Although growth hormone hypersecretion was controlled by surgery and medical treatment, these parameters did not improve - indicating a still increased risk for cardiovascular events.
Entities:
Keywords:
Acromegaly; mean platelet volume; platelet function analysis
Authors: A Sartorio; M Cattaneo; P Bucciarelli; B Bottasso; S Porretti; P Epaminonda; G Faglia; M Arosio Journal: Exp Clin Endocrinol Diabetes Date: 2000 Impact factor: 2.949
Authors: Paul Harrison; Ian Mackie; Anthony Mathur; Monique S C Robinson; Ying Hong; Jorge D Erusalimsky; Samuel J Machin; John F Martin Journal: Blood Coagul Fibrinolysis Date: 2005-11 Impact factor: 1.276
Authors: Martin Frossard; Ingrid Fuchs; Judith M Leitner; Kety Hsieh; Marianne Vlcek; Heidrun Losert; Hans Domanovits; Wolfgang Schreiber; Anton N Laggner; Bernd Jilma Journal: Circulation Date: 2004-08-16 Impact factor: 29.690
Authors: Antonio Mestron; Susan M Webb; Ricardo Astorga; Pedro Benito; Miguel Catala; Sonia Gaztambide; Jose-Manuel Gomez; Irene Halperin; Tomas Lucas-Morante; Basilio Moreno; Gabriel Obiols; Pedro de Pablos; Concha Paramo; Antonio Pico; Elena Torres; Cesar Varela; Jose-Antonio Vazquez; Juana Zamora; Merce Albareda; Montserrat Gilabert Journal: Eur J Endocrinol Date: 2004-10 Impact factor: 6.664